Randomized crossover trial of Granisetron/Dexamethasone/Aprepitant versus Palonosetron/Dexamethasone/Aprepitant for the prevention of nausea and vomiting in patients receiving receiving Cisplatin containing chemotherapy for head and neck cancer

INTERVENTION: Aprepitant is administered orally at 125 mg/body 1 hour or 1 hour and half before Cisplatin administration. On day 2 and 3, Aprepitant is administrated orally at 80 mg/body. Granisetron 40 ug/body and Dexamethasone 12.3 mg/body are administered intravenously 30 min before Cisplatin administration. On day 2 and 3, Granisetron 40 ug/body and Dexamethasone 6.6 mg/body are administrated. Aprepitant is administered orally at 125 mg/body 1 hour or 1 hour and half before Cisplatin administration. On day 2 and 3, Aprepitant is administrated orally at 80 mg/body. Palonosetron 0.75 mg/body and Dexamethasone 12.3 mg/body are administered intravenously 30 min before Cisplatin administration. On day 2 and 3, Dexamethasone 6.6 mg/body are administrated. CONDITION: head and neck cancer PRIMARY OUTCOME: the proportion of patients with a Complete Protection during the overall phase(0‐120 h postchemotherapy), the proportion of patients with a Complete Response during the overall phase SECONDARY OUTCOME: 1)the proportion of patients with a Complete Protection during; the acute phase (0‐24 h postchemotherapy) and the delayed; phase (24‐120 h postchemotherapy); 2)the proportion of patients with a Complete Response during the overall phase and the acute phase and the delayed phase; 3)the proportion of patients with a Complete Control during the overall phase and the acute phase and the delayed phase; 4)the proportion of patients without nausea; 5)the proportion of patients without emesis; 6)time to treatment failure; 7)safety INCLUSION CRITERIA: 1) histologically or cytologically confirmed head and neck cancer 2) stage III‐IV head and neck cancer 3) without prior treatment 4) age: >=20 and <75 5) patients who are scheduled to receive high emetogenic chemotherapy (Cisplatin >=60 mg/m2) 6) sufficient function of important organs a)WBC: >=3,000/mm3 b)AST: <100 IU/L c)ALT: <100 IU.L d)Ccr: >=60 ml/min/body 7) Performance Statues: 0‐1(ECOG) 8) written informed consent